Английская Википедия:Danoprevir

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Danoprevir (INN)[1] is an orally available[2] 15-membered macrocyclic peptidomimetic inhibitor of NS3/4A HCV protease.[3] It contains acylsulfonamide, fluoroisoindole and tert-butyl carbamate moieties. Danoprevir is a clinical candidate based on its favorable potency profile against multiple HCV genotypes 1–6 and key mutants (GT1b, IC50 = 0.2–0.4 nM; replicon GT1b, EC50 = 1.6 nM).[4] Danoprevir has been evaluated in an open-label, single arm clinical trial in combination with ritonavir for treating COVID-19[5] and favourably compared to lopinavir/ritonavir in a second trial.[6]

History

Danaoprevir was initially developed by Array BioPharma then licensed to Roche for further development and commercialization. In 2013, Danoprevir was licensed to Ascletis by Roche for development and production in China under the tradename Ganovo.[7][8]

References

Шаблон:Reflist

Further reading

Шаблон:Refbegin Шаблон:Cite journal Шаблон:Refend

Шаблон:RNA antivirals Шаблон:Portal bar


Шаблон:Antiinfective-drug-stub Шаблон:COVID-19-stub